Table 2 KEGG pathways of enriched genes
No | KEGG ID | KEGG term | P-adjust | Count |
|---|---|---|---|---|
1 | hsa04060 | Cytokine–cytokine receptor interaction | 8.57E−26 | 54 |
2 | hsa04062 | Chemokine signaling pathway | 2.99E−17 | 36 |
3 | hsa04514 | Cell adhesion molecules (CAMs) | 8.74E−12 | 26 |
4 | hsa04640 | Hematopoietic cell lineage | 3.57E−15 | 25 |
5 | hsa04380 | Osteoclast differentiation | 1.10E−10 | 23 |
6 | hsa04650 | Natural killer cell mediated cytotoxicity | 4.65E−08 | 20 |
7 | hsa05150 | Staphylococcus aureus infection | 3.54E−11 | 18 |
8 | hsa04660 | T cell receptor signaling pathway | 1.04E−06 | 16 |
9 | hsa05152 | Tuberculosis | 8.60E−04 | 16 |
10 | hsa04064 | NF-kappa B signaling pathway | 5.23E−06 | 15 |
11 | hsa04620 | Toll-like receptor signaling pathway | 8.06E−06 | 15 |
12 | hsa05322 | Systemic lupus erythematosus | 1.18E−04 | 15 |
13 | hsa05340 | Primary immunodeficiency | 4.36E−11 | 14 |
14 | hsa05323 | Rheumatoid arthritis | 8.06E−06 | 14 |
15 | hsa05142 | Chagas disease | 3.04E−05 | 14 |
16 | hsa04659 | Th17 cell differentiation | 4.29E−05 | 14 |
17 | hsa04145 | Phagosome | 1.56E−03 | 14 |
18 | hsa04630 | JAK-STAT signaling pathway | 2.62E−03 | 14 |
19 | hsa05332 | Graft-versus-host disease | 2.84E−09 | 13 |
20 | hsa05162 | Measles | 1.95E−03 | 13 |
21 | hsa05133 | Pertussis | 3.05E−05 | 12 |
22 | hsa04611 | Platelet activation | 2.50E−03 | 12 |
23 | hsa04610 | Complement and coagulation cascades | 2.22E−04 | 11 |
24 | hsa04658 | Th1 and Th2 cell differentiation | 8.49E−04 | 11 |
24 | hsa04672 | Intestinal immune network for IgA production | 2.12E−05 | 10 |
26 | hsa05144 | Malaria | 2.12E−05 | 10 |
27 | hsa04662 | B cell receptor signaling pathway | 1.95E−03 | 9 |
28 | hsa05330 | Allograft rejection | 1.40E−04 | 8 |
29 | hsa04940 | Type I diabetes mellitus | 3.30E−04 | 8 |
30 | hsa05320 | Autoimmune thyroid disease | 1.36E−03 | 8 |